214117-50-7

Basic information

• Product Name: 4-(4-BROMOPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE
• Synonyms: 4-(4-BROMOPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE;4-(4-Bromophenyl)-1H-1,2,4-triazol-5(4H)-one;3H-1,2,4-Triazol-3-one, 4-(4-broMophenyl)-2,4-dihydro-;4-(4-bromophenyl)-2H-1,2,4-triazol-3(4H)-one;-1H-1,2,4-triazol-5(4H)
• CAS NO: 214117-50-7
• Molecular Formula: C₈H₆BrN₃O
• Molecular Weight: 240.06
• Mol File: 214117-50-7.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.78
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-(4-BROMOPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-BROMOPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE(214117-50-7)
• EPA Substance Registry System: 4-(4-BROMOPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE(214117-50-7)

Safety Data

• Hazardous Substances Data: 214117-50-7(Hazardous Substances Data)

Usage

General Description

4-(4-Bromophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one is a chemical compound that belongs to the class of triazolone derivatives. It is a yellow solid at room temperature and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 4-(4-BROMOPHENYL)-2,4-DIHYDRO-3H-1,2,4-TRIAZOL-3-ONE has been studied for its potential biological activities, including antifungal, antimicrobial, and antitumor properties. It is also known for its ability to inhibit certain enzymes and receptors, making it a valuable tool in drug discovery and development. 4-(4-Bromophenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one is a versatile building block in organic chemistry with various potential applications in medicinal and agricultural fields.

Upstream product

• 2493-02-9 4-bromophenyl isocyanate 
• 624-84-0 formic acid hydrazide 
• 6294-89-9 hydrazinecarboxylic acid methyl ester 
• 106-40-1 4-bromo-aniline 
• 149-73-5 trimethyl orthoformate 
• 2646-26-6 4-(4-bromophenyl)semicarbazide 
• 3473-63-0 formamidine acetic acid 
• 463-52-5 formamidine 

Downstream Products

• 214117-54-1 4-(4-Bromo-phenyl)-2-((S)-sec-butyl)-2,4-dihydro-[1,2,4]triazol-3-one 
• 648416-96-0 2,4-dihydro-4-(4-bromophenyl)-2-[(2S,3R)-(3-hydroxy-2-butyl)]-3H-1,2,4-triazol-3-one 
• 199797-85-8 (2R,4S)-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-[(2S,3R)-(3-hydroxy-2-butyl)]-3H-1,2,4-triazol-3-one 
• 214117-52-9 2,4-dihydro-4-(4-bromophenyl)-2-[(2S,3R)-[3-(1,1-dimethylethyl)dimethylsiloxy]-but-2-yl]-3H-1,2,4-triazol-3-one 
• 214117-56-3 (2R,4S)-4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-[(2S,3R)-3-[(1,1-dimethylethyl)dimethylsiloxy-2-butyl]]-3H-1,2,4-triazol-3-one 
• 153896-47-0 (S)-2-(sec-butyl)-4-(4-(4-(4-methoxyphenyl)piperazin-1-yl)phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one 
• 864932-42-3 4-(4-bromophenyl)-1-isopropyl-1H-1,2,4-triazol-5(4H)-one 
• 895135-85-0 C₁₈H₂₃BrN₄O₃ 
• 1312809-83-8 4-(4-bromophenyl)-1-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one 
• 1346235-16-2 C₁₁H₁₁Br₂N₃O 
• 1346235-56-0 1-(3-(4-(2-(2,4-difluorophenyl)-2-hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl) piperazin-1-yl)propyl)-4-(4-bromophenyl)-1H-1,2,4-triazol-5(4H)-one 
• 1346235-36-6 C₁₅H₂₀BrN₅O 
• 1365802-72-7 4-[4-(4-{[3,5-bis(trifluoromethyl)phenyl]amino}phthalazin-1-yl)phenyl]-2,4-dihydro-3H-1,2,4-triazol-3-one 

Relevant articles and documents

NOVEL ARYL OR HETEROARYL TRIAZOLONE DERIVATIVES OR SALTS THEREOF, OR PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME

The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

Design, synthesis and antifungal evaluation of 1-(2-(2,4-difluorophenyl)-2- hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one

Based on the structure of the active site of cytochrome P450 14α-demethylase (CYP51) and the conclusions of the structure-activity relationships of azole antifungals, a series of 1-(2-(2,4-difluoro-phenyl)-2- hydroxy-3-(1H-1,2,4-triazol-1-yl)propyl)-1H-1,2,4-triazol-5(4H)-one of fluconazole analogs was synthesized. All compounds were characterized by IR, HRMS, 1HNMR and 13C NMR spectroscopic analysis. Results of preliminary antifungal in vitro test using eight human pathogenic species showed that some compounds displayed comparable or even better antifungal activities than reference drug fluconazole and that compound 3i exhibited significant activity against Candida albicans being worthy of further optimization.

Total synthesis of (2R,4S,2′S,3′R)-hydroxyitraconazole: Implementations of a recycle protocol and a mild and safe phase-transfer reagent for preparation of the key chiral units

A convergent total synthesis of enantiomerically-pure (2R,4S,2′S, 3′R)-hydroxyitraconazole 1b is described. The left dioxolane portion of the molecule was prepared in good yield by the conversion of (S)-10 to the corresponding enantiomerically and diastereomerically-pure acetonide (2R,4R)-3 by a recycle protocol involving diastereoselective crystallization of the tosylate salt, followed by re-equilibration of the mother liquor and crystallization. The right-hand triazolone moeity (2S,3R)-4 was generated by alkyaltion of triazolone 6 with enantiomerically pure cyclic sulfate (4R,5R)-7 under mild and essentially non-hazardous reaction conditions (TDA-1, K 2CO3, acetonitrile).